These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19304374)

  • 1. Editorial comment on: Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram.
    Briganti A
    Eur Urol; 2009 Oct; 56(4):667-8. PubMed ID: 19304374
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram.
    Chun FK; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Stillebroer AB; van Gils MP; Schalken JA; Fradet Y; Marks LS; Ellis W; Partin AW; Haese A
    Eur Urol; 2009 Oct; 56(4):659-67. PubMed ID: 19304372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol 2009;56:659-68.
    Morote J
    Eur Urol; 2010 Jan; 57(1):e1; author reply e2-3. PubMed ID: 19853371
    [No Abstract]   [Full Text] [Related]  

  • 4. External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome.
    Auprich M; Haese A; Walz J; Pummer K; de la Taille A; Graefen M; de Reijke T; Fisch M; Kil P; Gontero P; Irani J; Chun FK
    Eur Urol; 2010 Nov; 58(5):727-32. PubMed ID: 20619529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
    Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
    Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Value of urinary PCA3 test for prostate cancer diagnosis].
    Vlaeminck-Guillem V; Ruffion A; Andre J
    Prog Urol; 2008 May; 18(5):259-65. PubMed ID: 18538269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Prostate Cancer gene 3 assay: indications for use in clinical practice.
    Schilling D; de Reijke T; Tombal B; de la Taille A; Hennenlotter J; Stenzl A
    BJU Int; 2010 Feb; 105(4):452-5. PubMed ID: 19930176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.
    Nakanishi H; Groskopf J; Fritsche HA; Bhadkamkar V; Blase A; Kumar SV; Davis JW; Troncoso P; Rittenhouse H; Babaian RJ
    J Urol; 2008 May; 179(5):1804-9; discussion 1809-10. PubMed ID: 18353398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progensa™ PCA3 test for prostate cancer.
    Durand X; Moutereau S; Xylinas E; de la Taille A
    Expert Rev Mol Diagn; 2011 Mar; 11(2):137-44. PubMed ID: 21405964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting prostate biopsy outcome using a PCA3-based nomogram in a Polish cohort.
    Salagierski M; Mulders P; Schalken JA
    Anticancer Res; 2013 Feb; 33(2):553-7. PubMed ID: 23393348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCA3: a molecular urine assay for predicting prostate biopsy outcome.
    Deras IL; Aubin SM; Blase A; Day JR; Koo S; Partin AW; Ellis WJ; Marks LS; Fradet Y; Rittenhouse H; Groskopf J
    J Urol; 2008 Apr; 179(4):1587-92. PubMed ID: 18295257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer.
    Hessels D; van Gils MP; van Hooij O; Jannink SA; Witjes JA; Verhaegh GW; Schalken JA
    Prostate; 2010 Jan; 70(1):10-6. PubMed ID: 19708043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interpretation of the prostate cancer gene 3 in reference to the individual clinical background: implications for daily practice.
    Schilling D; Hennenlotter J; Munz M; Bökeler U; Sievert KD; Stenzl A
    Urol Int; 2010; 85(2):159-65. PubMed ID: 20424427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate impact of ultrasound-guided prostate biopsies on PCA3 score.
    Larré S; Ronsin C; Irani J
    Eur Urol; 2010 Jun; 57(6):1121-2. PubMed ID: 20227169
    [No Abstract]   [Full Text] [Related]  

  • 15. New tests for prostate cancer may be nearing the clinic.
    Tuma RS
    J Natl Cancer Inst; 2010 Jun; 102(11):752-4. PubMed ID: 20498428
    [No Abstract]   [Full Text] [Related]  

  • 16. Urinary PCA3 score predicts prostate cancer multifocality.
    Vlaeminck-Guillem V; Devonec M; Colombel M; Rodriguez-Lafrasse C; Decaussin-Petrucci M; Ruffion A
    J Urol; 2011 Apr; 185(4):1234-9. PubMed ID: 21334023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions.
    de la Taille A; Irani J; Graefen M; Chun F; de Reijke T; Kil P; Gontero P; Mottaz A; Haese A
    J Urol; 2011 Jun; 185(6):2119-25. PubMed ID: 21496856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.
    Haese A; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; van Gils MP; Schalken JA
    Eur Urol; 2008 Nov; 54(5):1081-8. PubMed ID: 18602209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.
    Marks LS; Fradet Y; Deras IL; Blase A; Mathis J; Aubin SM; Cancio AT; Desaulniers M; Ellis WJ; Rittenhouse H; Groskopf J
    Urology; 2007 Mar; 69(3):532-5. PubMed ID: 17382159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular PCA3 diagnostics on prostatic fluid.
    van Gils MP; Cornel EB; Hessels D; Peelen WP; Witjes JA; Mulders PF; Rittenhouse HG; Schalken JA
    Prostate; 2007 Jun; 67(8):881-7. PubMed ID: 17440939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.